Literature DB >> 30632086

Long-term Therapeutic Effects of Extracorporeal Shock Wave-Assisted Melatonin Therapy on Mononeuropathic Pain in Rats.

Chien-Hui Yang1, Hon-Kan Yip2,3,4,5,6, Hung-Fei Chen7, Tsung-Cheng Yin8, John Y Chiang9, Pei-Hsun Sung2, Kun-Chen Lin1, Yu-Huan Tsou1, Yi-Ling Chen2, Yi-Chen Li2, Tien-Hung Huang2, Chi-Ruei Huang2, Chi-Wen Luo2, Kuan-Hung Chen10,11.   

Abstract

We evaluated the ability of extracorporeal shock wave (ECSW)-assisted melatonin (Mel) therapy to offer an additional benefit for alleviating the neuropathic pain (NP) in rats. Left sciatic nerve was subjected to chronic constriction injury (CCI) to induce NP. Animals (n = 30) were randomized into group 1 (sham-operated control), group 2 (CCI only), group 3 (CCI + ECSW), group 4 (CCI + Mel) and group 5 (CCI + ECSW + Mel). By days 15, 22 and 29 after CCI, the thermal paw withdrawal latency (TPWL) and mechanical paw withdrawal threshold (MPWT) were highest in group 1, lowest in group 2, significantly higher in group 5 than in groups 3 and 4, but they showed no difference between the later two groups (all p < 0.0001). The protein expressions of inflammatory (TNF-α, NF-κB, MMP-9, IL-1ß), oxidative-stress (NOXs-1, -2, -4, oxidized protein), apoptotic (cleaved-caspase3, cleaved-PARP), DNA/mitochondrial-damaged (γ-H2AX/cytosolic-cytochrome C), microglia/astrocyte activation (ox42/GFAP), and MAPKs [phosphorylated (p)-p38, p-JNK, p-ERK] biomarkers in dorsal root ganglia neurons (DRGs) and in spinal dorsal horn were exhibited an opposite pattern of TPWL among the five groups (all p < 0.0001). Additionally, protein expressions of Nav.1.3, Nav.1.8 and Nav.1.9 in sciatic nerve exhibited an identical pattern to inflammation among the five groups (all p < 0.0001). The numbers of cellular expressions of MAPKs (p-ERK1/2+/peripherin + cells, p-ERK1/2+/NF200 + cells and p-JNK+/peripherin + cells, p-JNK+/NF200 + cells) and voltage-gated sodium channels (Nav.1.8+/peripherin + cells, Nav.1.8+/NF200 + cells, Nav.1.9+/peripherin + cells, Nav.1.9+/NF200 + cells) in small and large DRGs displayed an identical pattern to inflammation among the five groups (all p < 0.0001). In conclusion, the synergistic effect of combined ECSW-Mel therapy is superior to either one alone for long-term improvement of mononeuropathic pain-induced by CCI in rats.

Entities:  

Keywords:  Behavior test; Dorsal root ganglion; Inflammation; Oxidative stress; Protein kinase; Spinal dorsal horn

Mesh:

Substances:

Year:  2019        PMID: 30632086     DOI: 10.1007/s11064-018-02713-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  6 in total

Review 1.  The Effects of the Exposure of Musculoskeletal Tissue to Extracorporeal Shock Waves.

Authors:  Tobias Wuerfel; Christoph Schmitz; Leon L J Jokinen
Journal:  Biomedicines       Date:  2022-05-06

2.  Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial.

Authors:  Lu Chen; Ruihao Zhou; Fuguo Sun; Yan Weng; Ling Ye; Pingliang Yang
Journal:  Trials       Date:  2020-07-08       Impact factor: 2.279

Review 3.  Role of Melatonin in the Regulation of Pain.

Authors:  Shanshan Xie; Wenguo Fan; Hongwen He; Fang Huang
Journal:  J Pain Res       Date:  2020-02-07       Impact factor: 3.133

Review 4.  Application of extracorporeal shock wave therapy in nervous system diseases: A review.

Authors:  Juan Guo; Hong Hai; Yuewen Ma
Journal:  Front Neurol       Date:  2022-08-17       Impact factor: 4.086

5.  Synergic Effect of Early Administration of Probiotics and Adipose-Derived Mesenchymal Stem Cells on Alleviating Inflammation-Induced Chronic Neuropathic Pain in Rodents.

Authors:  Kuan-Hung Chen; Hung-Sheng Lin; Yi-Chen Li; Pei-Hsun Sung; Yi-Ling Chen; Tsung-Cheng Yin; Hon-Kan Yip
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

6.  Adjuvant use of melatonin for relieving symptoms of painful diabetic neuropathy: results of a randomized, double-blinded, controlled trial.

Authors:  Maryam Shokri; Firozeh Sajedi; Younes Mohammadi; Maryam Mehrpooya
Journal:  Eur J Clin Pharmacol       Date:  2021-06-13       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.